DMT vs 5-MeO-DMT (and DMT vs ayahuasca)
Educational only. dmt.clinic is operated by AdvancedCare USA Inc. It is not a clinic, does not give medical advice, does not refer patients, and does not sell substances or paraphernalia. N,N-DMT and 5-MeO-DMT are Schedule I controlled substances in the United States (21 U.S.C. §812; 21 C.F.R. §1308.11; as of 2026-07-21). This page distinguishes molecules and research themes. It is not a buyer’s guide, field guide, or “which one should I take” article.
Three things people confuse
| Name | What it is | Common mix-up |
|---|---|---|
| N,N-DMT | A single tryptamine molecule | Called simply “DMT” in casual speech |
| 5-MeO-DMT | A different tryptamine molecule | Treated as “the same as DMT” online |
| Ayahuasca | A traditional brew (multi-component) | Treated as pure DMT in a cup |
If you only remember one sentence: 5-MeO-DMT is not “stronger DMT” in a simple sense — it is a different compound with a different research profile. For receptor detail, see pharmacology.
Different molecules, different receptor emphasis
Both compounds are indolealkylamines. N,N-DMT is widely discussed through the lens of 5-HT2A agonism shared with classical psychedelics. 5-MeO-DMT is repeatedly described in the literature as engaging 5-HT1A strongly in addition to other serotonergic targets, which is one proposed reason subjective reports differ.
These are laboratory and clinical-research distinctions. They do not authorize use, and they do not translate into a public “which is safer” ranking without a full risk discussion (see harm reduction).
Subjective-research differences (reported, not prescribed)
Human and survey research language often clusters as follows — as reported in research and observational literature, not as instructions for seeking an experience:
| Theme | N,N-DMT (frequent research language) | 5-MeO-DMT (frequent research language) |
|---|---|---|
| Visual phenomenology | Often rich visual content in reports | Often described as less “visual narrative” |
| Ego / self | Profound alterations common | Ego-dissolution / “intensity” frequently emphasized |
| Duration in experimental settings | Very short for non-infusion IV/smoked research contexts | Also short-acting in experimental descriptions |
| Entity encounters | Frequently catalogued in DMT phenomenology papers | Less central in many 5-MeO report clusters |
None of the above is a menu. Phenomenology catalogues exist because scientists study reports; they are not marketing copy and not a reason to seek illegal access.
DMT vs ayahuasca
Ayahuasca is not “oral DMT powder.” In the traditional Amazonian and research literature, it is a brew that typically combines:
- A plant source of N,N-DMT, and
- Banisteriopsis caapi (or related sources) containing β-carboline MAO-A inhibitors
The MAO-A inhibition is the standard pharmacological explanation for oral activity of DMT in the brew. Duration of the ayahuasca experience is commonly described in the literature as hours (often on the order of roughly 4–6 hours in ethnographic/clinical descriptions), which is a different time course from very short experimental N,N-DMT challenges.
Legal note (brief)
Ayahuasca still implicates DMT, a Schedule I substance under U.S. federal law. Narrow religious exemptions exist for specific named churches under RFRA litigation (notably Gonzales v. O Centro, 2006). That is not a general public exemption. Full page: legal status.
We do not provide brew recipes, plant ratios, or ceremonial how-tos.
5-MeO sources in nature and synthesis (descriptive only)
5-MeO-DMT occurs in the defensive secretion of the Sonoran Desert toad (Incilius alvarius, formerly Bufo alvarius) and in some plant species; it is also produced synthetically for research. Two non-negotiable educational points:
- Conservation and animal welfare. Wild toad populations and habitats face pressure from collection and habitat loss. Harvesting wild animals for psychoactive secretions is not framed here as acceptable practice. Prefer primary conservation literature and wildlife agencies over influencer content.
- No sourcing. We will not list vendors, geographic “hotspots” for collection, or synthetic supply channels.
Different risk profiles (high level)
Both compounds can produce psychological distress and cardiovascular stress. 5-MeO-DMT is particularly associated in toxicology and case literature with severe hypertension and cardiovascular/respiratory adverse events, including fatalities discussed in case reports — a reason research protocols use medical monitoring and a reason this site refuses “how to use” content. Serotonergic drug–drug interactions matter for both (SSRIs/SNRIs/MAOIs/lithium and related agents). Details without use instructions: harm reduction.
Quick comparison table
| Dimension | N,N-DMT | 5-MeO-DMT | Ayahuasca brew |
|---|---|---|---|
| Chemical identity | Single molecule | Different single molecule | Multi-component preparation |
| Federal U.S. status (as of 2026-07-21) | Schedule I | Schedule I (scheduled 2011) | Contains Schedule I DMT |
| Typical research focus | Phenomenology, imaging, PK | Separate depression-oriented development programs among others | Ethnopharmacology + clinical ayahuasca studies (distinct literature) |
| This site’s role | Education | Education | Education — no recipes |
What we will never publish on this topic
- “Which is better for depression/anxiety” as consumer advice
- Dose charts or route tutorials
- Toad- milking or plant-extraction instructions
- Retreat or underground-provider directories
For research participation as research, not treatment shopping: clinical research and the homepage trial finder.
Sources (checked 2026-07-21)
- Receptor pharmacology and tryptamine reviews (Nichols and related literature).
- Strassman-era N,N-DMT human studies; Imperial College DMT neuroimaging series (Timmermann et al. 2019, 2023).
- Observational/survey literature on 5-MeO-DMT (e.g. Davis et al. 2019 and subsequent work — interpret cautiously).
- Ethnopharmacology of ayahuasca (MAO-A / β-carboline + DMT interaction).
- Incilius alvarius conservation and wildlife guidance (species formerly Bufo alvarius).
- DEA/eCFR Schedule I listings; Gonzales v. O Centro (2006).
Last editorial check: 2026-07-21. Educational comparison only. Not medical or legal advice.